Immunotherapies in development for the treatment of Hodgkin lymphoma
| Trial | Agents investigated | Agent description | Primary outcome for assessment |
| CheckMate 812 (NCT03138499) | Nivolumab+BV vs BV monotherapy in patients with R/R cHL, not eligible for autoSCT | ICI, ADC | PFS |
| NCTN S1826 (NCT03907488) | Nivolumab+AVD vs BV+AVD (A-AVD) for first-line treatment of stage III or IV cHL | ICI | PFS |
| MK-3475–204/KEYNOTE-204 (NCT02684292) | Pembrolizumab vs BV for R/R cHL | ICI | PFS, OS |
| NCT02572167 | BV+nivolumab for R/R cHL | ICI, ADC | Rate of AEs, CR rate |
A-AVD, brentuximab vedotin, doxorubicin, vinblastine, dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ADC, antibody-drug conjugate; AEs, adverse events; BV, brentuximab vedotin; cHL, classical Hodgkin lymphoma; CR, complete response; ICI, immune checkpoint inhibitor; mAb, monoclonal antibody; OS, overall survival; PFS, progression-free survival; R/R, relapsed or refractory.